Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar. Closed at $2.80, 29% below $3.93, its close on the day of its Sep 30 private placement. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$12.7MCash on Hand
22.1mo Cash Runway
Follow NMAD by emailGet an email when NMAD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NMAD, unsubscribe in one click. Privacy
📣 What NMAD Says Is Next
in 2026 · “The global battery energy storage market serving data centers is projected to grow from approximately $4.96 billion in 2026 to $18.79 billion by 2036, reflecting a compound annual growth rate of roughly 14%, as AI and hyperscale computing workloads continue to drive demand for resilient, rapidly deployable backup power.”
Company press release, Jul 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 16, 2026 ·
Leadership Reported Q3 2026 10-Q filing and business update: backlog exceeds $30 million, deferred revenue rose to $9.6 million, and Michael Hilmer was named Chairman and Interim CEO after Geordan Pursglove stepped down. Production ramp is planned for Q1 2027. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Leadership CEO Geordan Pursglove stepped down and left the board on Nov 9, 2026, receiving a $600,000 severance and 1,500,000 RSUs for consulting through Jan 31, 2027. Michael Hilmer was appointed to the board and named Executive Chairman, at $20,000 per month. Form 8-K · SEC filing · Press release
Oct 6, 2026 ·
Launched a 2026 Nationwide Mobile Power Demonstration Tour with 26 stops across the Mountain West, Northeast and Southwest in October and November, showcasing its Voyager and Voyager Falcon battery energy storage systems. No financial results or deal terms were disclosed. Form 8-K · SEC filing · Press release
Sep 17, 2026 ·
Restructuring Files audited financials for NOMAD Transportable Power Systems for 2025 and 2024, unaudited six-month 2026 financials, and pro forma combined statements tied to the Lixte Biotechnology merger, which closed July 1, 2026. Form 8-K/A · SEC filing · Press release
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
NMAD holds $12.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.7M/quarter from operations,
an estimated runway of 22.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:90 · High
Cash runway 6 months +30
ATM program on file since Jan 2025 +15
Shelf registration (S-3, Apr 2024) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.10-Q, Nov 2026
Share count 18,419,632 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full NMAD picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NMAD and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.